Health Canada approves second drug targeting underlying cause of Alzheimer’s disease - The Globe and Mail
Sentiment Mix
Geography
Expert Signals
Global News - Main Feed
source • 1 mention
Politics - Google News CA Headlines
source • 1 mention
AI-Generated Claims
Generated from linked receipts; click sources for full context.
‘Hopeful milestone': Health Canada approves 2nd drug to slow Alzheimer's.
Supported by 1 story
This is the second disease-slowing drug for Alzheimer's that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.
Supported by 1 story
Related Events
Innovation will provide solutions to Long COVID — the new chronic disease of our time
Uncategorized • 5/4/2026
U.S. Supreme Court temporarily restores full access to abortion pill
Policy & Regulation • 5/4/2026
What Doctors Want You to Know About Cannabis and Health - The New York Times
Uncategorized • 5/4/2026
University Health Network recruits senior NIH investigator, more than 70 global scientists - The Globe and Mail
Uncategorized • 5/4/2026
Mark Carney Pulls Canada Closer to Europe as Both Struggle With Trump
Uncategorized • 5/4/2026